Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1404

  • Filters activated: Field: Title/Abstract. Clear all
1.

The triad of diabetes ketoacidosis, hypertriglyceridemia and acute pancreatitis. How does it affect mortality and morbidity?: A 10-year analysis of the National Inpatient Sample.

Simons-Linares CR, Jang S, Sanaka M, Bhatt A, Lopez R, Vargo J, Stevens T, Chahal P.

Medicine (Baltimore). 2019 Feb;98(7):e14378. doi: 10.1097/MD.0000000000014378.

2.

Prevalence, treatment, and control of dyslipidemia in diabetic participants of two brazilian cohorts: a place far from heaven.

Martins NS, Mello DSS, Barreto J, Soares AAS, Breder I, Cunha J, Nadruz W, Coelho Filho OR, Matos-Souza JR, Coelho OR, Munhoz DB, Silva JCQE, Sposito AC, Carvalho LSF.

Rev Assoc Med Bras (1992). 2019 Jan;65(1):3-8. doi: 10.1590/1806-9282.65.1.3.

3.

Plasma Exchange for the Treatment of Transient Extreme Hypertriglyceridemia Associated with Diabetic Ketoacidosis and Acute Pancreatitis.

Donelli D, Morini L, Trenti C, Santi R, Arioli D, Negri EA.

Eur J Case Rep Intern Med. 2018 May 25;5(5):000853. doi: 10.12890/2018_000853. eCollection 2018.

4.

A randomized controlled trial of a herbal compound for improving metabolic parameters in diabetic patients with uncontrolled dyslipidemia.

Ghorbani A, Zarvandi M, Rakhshandeh H.

Endocr Metab Immune Disord Drug Targets. 2019 Feb 6. doi: 10.2174/1871530319666190206213420. [Epub ahead of print]

PMID:
30727929
5.

Association between Prescription and Control Status of Dyslipidemia and Hypertension among Japanese Patients with Diabetes.

Sakamoto M, Edo N, Takahashi S, Okamura E, Uno K, Morita K, Ishikawa T, Asahi K, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Fujimoto S, Narita I, Konta T, Kondo M, Kimura K, Ohashi Y, Watanabe T, Tsukamoto K.

J Atheroscler Thromb. 2019 Feb 6. doi: 10.5551/jat.47597. [Epub ahead of print]

6.

Diabetic Ketoacidosis Revealing a Severe Hypertriglyceridemia and Acute Pancreatitis in Type 1 Diabetes Mellitus.

Zaher FZ, Boubagura I, Rafi S, Elmghari G, Elansari N.

Case Rep Endocrinol. 2019 Jan 6;2019:8974619. doi: 10.1155/2019/8974619. eCollection 2019.

7.

A smartphone-assisted microfluidic chemistry analyzer using image-based colorimetric assays for multi-index monitoring of diabetes and hyperlipidemia.

Li J, Sun Y, Chen C, Sheng T, Liu P, Zhang G.

Anal Chim Acta. 2019 Apr 4;1052:105-112. doi: 10.1016/j.aca.2018.11.025. Epub 2018 Nov 15.

PMID:
30685028
8.

Adlay Bran Oil Suppresses Hepatic Gluconeogenesis and Attenuates Hyperlipidemia in Type 2 Diabetes Rats.

Tseng YH, Chang CW, Chiang W, Hsieh SC.

J Med Food. 2019 Jan;22(1):22-28. doi: 10.1089/jmf.2018.4237.

PMID:
30673500
9.

Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.

Wake M, Oh A, Onishi Y, Guelfucci F, Shimasaki Y, Teramoto T.

Atherosclerosis. 2018 Dec 29;282:19-28. doi: 10.1016/j.atherosclerosis.2018.12.026. [Epub ahead of print]

10.

Treatment of Diabetes, Obesity, Dyslipidemia, and Related Disorders with GPR119 Agonists.

Abdel-Magid AF.

ACS Med Chem Lett. 2018 Dec 24;10(1):14-15. doi: 10.1021/acsmedchemlett.8b00622. eCollection 2019 Jan 10. No abstract available.

PMID:
30655939
11.

Future perspectives of the pharmacological management of diabetic dyslipidemia.

Patti AM, Giglio RV, Papanas N, Rizzo M, Rizvi AA.

Expert Rev Clin Pharmacol. 2019 Feb;12(2):129-143. doi: 10.1080/17512433.2019.1567328. Epub 2019 Jan 22. Review.

PMID:
30644763
12.

Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: A cross-sectional study.

Das H, Banik S.

Diabetes Metab Syndr. 2019 Jan - Feb;13(1):252-257. doi: 10.1016/j.dsx.2018.09.006. Epub 2018 Sep 8.

PMID:
30641707
13.

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.

Balakumar P, Mahadevan N, Sambathkumar R.

Curr Mol Pharmacol. 2019 Jan 11. doi: 10.2174/1874467212666190111165015. [Epub ahead of print]

PMID:
30636619
14.

Action of corilagin on hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats.

Nandini HS, Naik PR.

Chem Biol Interact. 2019 Feb 1;299:186-193. doi: 10.1016/j.cbi.2018.12.012. Epub 2018 Dec 21.

PMID:
30582900
15.
16.

Dyslipidemia Is a Major Factor in Stem Cell Damage Induced by Uncontrolled Long-Term Type 2 Diabetes and Obesity in the Rat, as Suggested by the Effects on Stem Cell Culture.

Masouminia M, Gelfand R, Kovanecz I, Vernet D, Tsao J, Salas R, Castro K, Loni L, Rajfer J, Gonzalez-Cadavid NF.

J Sex Med. 2018 Dec;15(12):1678-1697. doi: 10.1016/j.jsxm.2018.09.019.

PMID:
30527052
17.

CCR5-Δ32 polymorphism is a genetic risk factor associated with dyslipidemia in patients with type 1 diabetes.

Słomiński B, Ławrynowicz U, Ryba-Stanisławowska M, Skrzypkowska M, Myśliwska J, Myśliwiec M.

Cytokine. 2018 Nov 9. pii: S1043-4666(18)30417-4. doi: 10.1016/j.cyto.2018.11.005. [Epub ahead of print]

PMID:
30420202
18.

Lipemia Retinalis, Macular Edema, and Vision Loss in a Diabetic Patient with a History of Type IV Hypertriglyceridemia and Pancreatitis.

Hinkle JW, Relhan N, Flynn HW Jr.

Case Rep Ophthalmol. 2018 Oct 2;9(3):425-430. doi: 10.1159/000493384. eCollection 2018 Sep-Dec.

19.

Perilla Oil Supplementation Improves Hypertriglyceridemia and Gut Dysbiosis in Diabetic KKAy Mice.

Wang F, Zhu H, Hu M, Wang J, Xia H, Yang X, Yang L, Sun G.

Mol Nutr Food Res. 2018 Dec;62(24):e1800299. doi: 10.1002/mnfr.201800299. Epub 2018 Nov 8.

PMID:
30358922
20.

Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.

Bhosle D, Bhosle V, Bobde J, Shaikh H, Kadam R.

J Assoc Physicians India. 2018 Mar;66(3):14-17.

PMID:
30341861

Supplemental Content

Loading ...
Support Center